Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes

IF 4.6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes & metabolism Pub Date : 2024-05-04 DOI:10.1016/j.diabet.2024.101542
Damien Denimal , Laurence Duvillard , Sarah Béland-Bonenfant , Béatrice Terriat , Jean-Paul Pais-de-Barros , Isabelle Simoneau , Alexia Rouland , Lina Houbachi , Benjamin Bouillet , Bruno Vergès , Jean-Michel Petit
{"title":"Plasma 16:0 ceramide as a marker of cardiovascular risk estimated by carotid intima-media thickness in people with type 2 diabetes","authors":"Damien Denimal ,&nbsp;Laurence Duvillard ,&nbsp;Sarah Béland-Bonenfant ,&nbsp;Béatrice Terriat ,&nbsp;Jean-Paul Pais-de-Barros ,&nbsp;Isabelle Simoneau ,&nbsp;Alexia Rouland ,&nbsp;Lina Houbachi ,&nbsp;Benjamin Bouillet ,&nbsp;Bruno Vergès ,&nbsp;Jean-Michel Petit","doi":"10.1016/j.diabet.2024.101542","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>New tools are required to better assess cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM). Plasma ceramides emerge as promising candidates, given their substantial influence on the pathogenesis of both T2DM and atherosclerosis. The current study aimed to investigate whether plasma ceramides in patients with T2DM are a predictive factor for carotid intima-media thickness (CIMT), a well-established noninvasive marker for atherosclerosis that predicts adverse cardiovascular outcomes.</p></div><div><h3>Methods</h3><p>A lipidomic analysis was carried out on the circulating ceramides of a large cohort consisting of 246 patients with T2DM who underwent a high-resolution real-time B ultrasonography to measure CIMT.</p></div><div><h3>Results</h3><p>Both plasma 16:0 ceramide and the 16:0/24:0 ceramide ratio were positively associated with CIMT, even after adjustment for traditional cardiovascular risk factors [standardized β ± standard error: 0.168 ± 0.072 (<em>P</em> = 0.020) and 0.180 ± 0.068 (<em>P</em> = 0.009), respectively]. Similar independent associations were found with respect to the prediction of CIMT ≥ 0.80 mm [β = 8.07 ± 3.90 (<em>P</em> = 0.038) and 16.5 ± 7.0 (<em>P</em> = 0.019), respectively]. The goodness-of-fit for multivariate models in predicting CIMT was 5.7 and 7.6 times higher when plasma 16:0 ceramide or the 16:0/24:0 ceramide ratio were included in combination with traditional cardiovascular risk factors (<em>P</em> = 0.020 and 0.015, respectively). This reached a 3.1 and 10.0-fold increase regarding the ability to predict CIMT ≥ 0.80 mm (<em>P</em> = 0.039 and 0.008, respectively).</p></div><div><h3>Conclusions</h3><p>Our findings suggest that 16:0 ceramide and the 16:0/24:0 ceramide ratio may serve as plasma biomarkers to improve cardiovascular risk assessment in individuals with T2DM.</p></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S126236362400034X/pdfft?md5=6dd6dda1006545cc52403e0d3d490413&pid=1-s2.0-S126236362400034X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S126236362400034X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim

New tools are required to better assess cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM). Plasma ceramides emerge as promising candidates, given their substantial influence on the pathogenesis of both T2DM and atherosclerosis. The current study aimed to investigate whether plasma ceramides in patients with T2DM are a predictive factor for carotid intima-media thickness (CIMT), a well-established noninvasive marker for atherosclerosis that predicts adverse cardiovascular outcomes.

Methods

A lipidomic analysis was carried out on the circulating ceramides of a large cohort consisting of 246 patients with T2DM who underwent a high-resolution real-time B ultrasonography to measure CIMT.

Results

Both plasma 16:0 ceramide and the 16:0/24:0 ceramide ratio were positively associated with CIMT, even after adjustment for traditional cardiovascular risk factors [standardized β ± standard error: 0.168 ± 0.072 (P = 0.020) and 0.180 ± 0.068 (P = 0.009), respectively]. Similar independent associations were found with respect to the prediction of CIMT ≥ 0.80 mm [β = 8.07 ± 3.90 (P = 0.038) and 16.5 ± 7.0 (P = 0.019), respectively]. The goodness-of-fit for multivariate models in predicting CIMT was 5.7 and 7.6 times higher when plasma 16:0 ceramide or the 16:0/24:0 ceramide ratio were included in combination with traditional cardiovascular risk factors (P = 0.020 and 0.015, respectively). This reached a 3.1 and 10.0-fold increase regarding the ability to predict CIMT ≥ 0.80 mm (P = 0.039 and 0.008, respectively).

Conclusions

Our findings suggest that 16:0 ceramide and the 16:0/24:0 ceramide ratio may serve as plasma biomarkers to improve cardiovascular risk assessment in individuals with T2DM.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血浆 16:0 神经酰胺作为 2 型糖尿病患者颈动脉内膜中层厚度估测的心血管风险标志物。
目的:--需要新的工具来更好地评估 2 型糖尿病(T2DM)患者的心血管风险。鉴于血浆神经酰胺对 T2DM 和动脉粥样硬化的发病机制有重大影响,因此血浆神经酰胺成为有希望的候选物质。本研究旨在探讨 T2DM 患者的血浆神经酰胺是否是颈动脉内膜中层厚度(CIMT)的预测因素,CIMT 是动脉粥样硬化的公认无创标志物,可预测不良心血管后果。方法:- 对 246 名接受高分辨率实时 B 超测量 CIMT 的 T2DM 患者的循环神经酰胺进行了脂质组学分析:- 结果:即使调整了传统的心血管风险因素,血浆16:0神经酰胺和16:0/24:0神经酰胺比值仍与CIMT呈正相关[标准化β±标准误差:0.168±0.0.0]:分别为 0.168 ± 0.072 (P = 0.020) 和 0.180 ± 0.068 (P = 0.009)]。在预测 CIMT ≥ 0.80 mm 方面也发现了类似的独立关联[β = 8.07 ± 3.90(P = 0.038)和 16.5 ± 7.0(P = 0.019)]。当血浆 16:0 神经酰胺或 16:0/24:0 神经酰胺比值与传统的心血管风险因素相结合时,多变量模型预测 CIMT 的拟合优度分别提高了 5.7 倍和 7.6 倍(P = 0.020 和 0.015)。这使预测 CIMT ≥ 0.80 mm 的能力分别增加了 3.1 倍和 10.0 倍(P = 0.039 和 0.008):- 我们的研究结果表明,16:0 神经酰胺和 16:0/24:0 神经酰胺比值可作为血浆生物标志物,用于改善 T2DM 患者的心血管风险评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Diabetes & metabolism
Diabetes & metabolism 医学-内分泌学与代谢
CiteScore
12.00
自引率
4.20%
发文量
86
审稿时长
13 days
期刊介绍: A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.
期刊最新文献
Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report Editorial board Contents Association between gastrectomy and the risk of type 2 diabetes in gastric cancer survivors: A nationwide cohort study Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1